PE20191836A1 - Compuesto de insulina acilada - Google Patents
Compuesto de insulina aciladaInfo
- Publication number
- PE20191836A1 PE20191836A1 PE2019002403A PE2019002403A PE20191836A1 PE 20191836 A1 PE20191836 A1 PE 20191836A1 PE 2019002403 A PE2019002403 A PE 2019002403A PE 2019002403 A PE2019002403 A PE 2019002403A PE 20191836 A1 PE20191836 A1 PE 20191836A1
- Authority
- PE
- Peru
- Prior art keywords
- acillated
- insulin compound
- compound
- refers
- xaa
- Prior art date
Links
- -1 INSULIN COMPOUND Chemical class 0.000 title abstract 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un compuesto de insulina acilada de formula (I), donde Xaa es el aminoacido glicina o asparagina. Dicho compuesto reduce la glucosa en la sangre, siendo utiles en el tratamiento de la diabetes y/o hiperglucemia. Tambien se refiere a una composicion farmaceutica que contiene dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511690P | 2017-05-26 | 2017-05-26 | |
| PCT/US2018/033418 WO2018217573A1 (en) | 2017-05-26 | 2018-05-18 | Acylated insulin compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191836A1 true PE20191836A1 (es) | 2019-12-30 |
Family
ID=62528889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002403A PE20191836A1 (es) | 2017-05-26 | 2018-05-18 | Compuesto de insulina acilada |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10400021B2 (es) |
| EP (1) | EP3630165A1 (es) |
| JP (1) | JP6665349B2 (es) |
| KR (1) | KR102271057B1 (es) |
| CN (1) | CN110691608B (es) |
| AR (1) | AR112353A1 (es) |
| AU (1) | AU2018273777B2 (es) |
| BR (1) | BR112019021668A2 (es) |
| CA (1) | CA3065078C (es) |
| CL (1) | CL2019003259A1 (es) |
| CO (1) | CO2019012964A2 (es) |
| CR (1) | CR20190523A (es) |
| DO (1) | DOP2019000296A (es) |
| EA (1) | EA038073B1 (es) |
| EC (1) | ECSP19083930A (es) |
| IL (1) | IL270813B2 (es) |
| JO (1) | JOP20190273A1 (es) |
| MA (1) | MA49310A (es) |
| MX (1) | MX375982B (es) |
| PE (1) | PE20191836A1 (es) |
| PH (1) | PH12019502655A1 (es) |
| SA (1) | SA519410448B1 (es) |
| TW (1) | TWI672315B (es) |
| WO (1) | WO2018217573A1 (es) |
| ZA (1) | ZA201906955B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210102347A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체 |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN118772259A (zh) * | 2019-12-30 | 2024-10-15 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| JP7456007B2 (ja) * | 2020-05-15 | 2024-03-26 | イーライ リリー アンド カンパニー | 長時間作用アシル化インスリン化合物 |
| KR20250004935A (ko) | 2022-05-18 | 2025-01-08 | 프로토머 테크놀로지스 인크. | 방향족 붕소-함유 화합물 및 관련 인슐린 유사체 |
| WO2024051787A1 (zh) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | 一种长效酰化胰岛素衍生物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| JP2001521006A (ja) * | 1997-10-24 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | 不溶性インシュリン組成物 |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2435522T3 (es) | 2005-02-02 | 2013-12-20 | Novo Nordisk A/S | Derivados de insulina |
| WO2009022006A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| EP2178912B1 (en) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| EP2910569B1 (en) * | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| AU2009335712B2 (en) * | 2008-12-19 | 2015-09-17 | Indiana University Research And Technology Corporation | Insulin analogs |
| EP2976096B1 (en) | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| WO2014177623A1 (en) * | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
-
2017
- 2017-06-16 JO JOP/2019/0273A patent/JOP20190273A1/ar unknown
-
2018
- 2018-05-11 AR ARP180101254 patent/AR112353A1/es unknown
- 2018-05-11 TW TW107116025A patent/TWI672315B/zh active
- 2018-05-18 WO PCT/US2018/033418 patent/WO2018217573A1/en active Application Filing
- 2018-05-18 EP EP18729289.1A patent/EP3630165A1/en active Pending
- 2018-05-18 EA EA201992272A patent/EA038073B1/ru unknown
- 2018-05-18 MX MX2019014086A patent/MX375982B/es active IP Right Grant
- 2018-05-18 MA MA049310A patent/MA49310A/fr unknown
- 2018-05-18 JP JP2019520536A patent/JP6665349B2/ja active Active
- 2018-05-18 PE PE2019002403A patent/PE20191836A1/es unknown
- 2018-05-18 CN CN201880034670.1A patent/CN110691608B/zh active Active
- 2018-05-18 CR CR20190523A patent/CR20190523A/es unknown
- 2018-05-18 BR BR112019021668-5A patent/BR112019021668A2/pt unknown
- 2018-05-18 CA CA3065078A patent/CA3065078C/en active Active
- 2018-05-18 AU AU2018273777A patent/AU2018273777B2/en active Active
- 2018-05-18 IL IL270813A patent/IL270813B2/en unknown
- 2018-05-18 US US15/983,167 patent/US10400021B2/en active Active
- 2018-05-18 KR KR1020197034368A patent/KR102271057B1/ko active Active
-
2019
- 2019-08-01 US US16/529,095 patent/US10597436B2/en active Active
- 2019-10-22 ZA ZA2019/06955A patent/ZA201906955B/en unknown
- 2019-10-31 SA SA519410448A patent/SA519410448B1/ar unknown
- 2019-11-14 CL CL2019003259A patent/CL2019003259A1/es unknown
- 2019-11-19 CO CONC2019/0012964A patent/CO2019012964A2/es unknown
- 2019-11-22 DO DO2019000296A patent/DOP2019000296A/es unknown
- 2019-11-25 EC ECSENADI201983930A patent/ECSP19083930A/es unknown
- 2019-11-25 PH PH12019502655A patent/PH12019502655A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191836A1 (es) | Compuesto de insulina acilada | |
| PE20160781A1 (es) | Formulaciones de insulina de accion prolongada | |
| MX2017013337A (es) | Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia. | |
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| AR098576A1 (es) | Producto farmacéutico | |
| MA33442B1 (fr) | Préparations d'insuline contenant de la méthionine | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| ES2572267T3 (es) | Composiciones de insulina de acción súper rápida | |
| PE20161408A1 (es) | Composiciones de insulina de rapida accion | |
| UY32032A (es) | "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas" | |
| EA201890584A1 (ru) | Новые аналоги инсулина и их применение | |
| MY152172A (en) | Therapeutic agent for diabetes | |
| SA519401933B1 (ar) | تركيبات صيدلية تحتوي على الأنسولين | |
| PH12015501931B1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| NZ603614A (en) | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| MX2021010988A (es) | Derivados de insulina sensibles a la glucosa. | |
| JOP20210201A1 (ar) | مركب لخفض جلوكوز الدم | |
| MX2023013194A (es) | Compuesto inhibidor de atr que contiene sulfoximina. | |
| PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
| CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. | |
| DOP2016000096A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| CL2016001473A1 (es) | Compuesto analogo del glucogeno (glp-1) que comprende acido alfa aminobutirico para el tratamiento de hipoglicemia. | |
| CO2018003759A2 (es) | Tratamiento de la neuropatía periférica diabética usando células placentarias |